Skip to content

A study to evaluate the Safety, In-Use Tolerability and Efficacy of a test product in reducing acne and acne spots on the face.

A clinical study to evaluate safety, in-use tolerability and efficacy of Purifying Neem Face Wash in healthy subjects with mild to moderate acne and acne prone skin. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/074716
Enrollment
133
Registered
2024-10-04
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L709- Acne, unspecified

Interventions

Intervention1: Purifying Neem Face Wash: Approx. 3 ml of product will be applied twice a day (morning and evening) for 29 days. Control Intervention1: NIL: NIL

Sponsors

Himalaya Wellness Company
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Subjects with mild to moderate acne condition. OR Subjects who are prone to develop however with no existing acne. 2) Subjects with oily skin having Sebumeter measurement more than 150 (ug/cm2). 3) Subjects with acne marks/spots and post acne scar. 4) Subjects with visible facial pores.

Exclusion criteria

Exclusion criteria: 1) Subjects with drug induced acne as disclosed by subjects. 2) Subjects undergoing treatment for skin lightening or using other marketed skin lightening products during the study period or in the past 6 weeks. 3) Subjects who are receiving topical or systemic treatments for acne, acne marks and acne scars. 4) Subjects receiving medications (e.g., steroids or antihistamines) would compromise the study. 5) Chronic illness which may influence the cutaneous state.

Design outcomes

Primary

MeasureTime frame
To assess the efficacy of test product on acne or acne prone skin, based on clinical, instrumental and subjective evaluations done at predetermined time points.Timepoint: Day 01 (before application and 15 mins), Day 02 (24hrs), Day 03 (48 hrs), Day 04 (72 hrs), Day 05 (+ 01 day), Day 07 (+ 02 days), Day 15 (+ 02 days) and Day 29 (+ 02 days).

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Parth Joshi

Cliantha Research

ssethi@cliantha.com9825784942

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026